VF
ATOS icon

Virtu Financial’s Atossa Therapeutics ATOS Stock Holding History

Virtu Financial’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,451
Closed -$31K – 1454
2025
Q2 		$31K Buy
+2,451
New +$29.3K ﹤0.01% 1201
2025
Q1 		– Sell
-13,880
Closed -$197K – 1346
2024
Q4 		$197K Buy
13,880
+10,504
+311% +$205K 0.01% 897
2024
Q3 		$77K Sell
3,376
-1,632
-33% -$32.9K ﹤0.01% 947
2024
Q2 		$89K Sell
5,008
-588
-11% -$13K 0.01% 838
2024
Q1 		$151K Buy
+5,596
New +$89.9K 0.01% 845
2023
Q4 		– Sell
-5,382
Closed -$59K – 1554
2023
Q3 		$59K Sell
5,382
-406
-7% -$5.89K 0.01% 889
2023
Q2 		$109K Buy
+5,788
New +$70.2K 0.01% 1020
2021
Q4 		– Sell
-4,902
Closed -$240K – 1698
2021
Q3 		$240K Buy
4,902
+3,660
+295% +$213K 0.02% 825
2021
Q2 		$118K Sell
1,242
-16,887
-93% -$894K 0.01% 1159
2021
Q1 		$574K Sell
18,129
-225
-1% -$8.22K 0.04% 456
2020
Q4 		$262K Buy
+18,354
New +$425K 0.03% 706
2019
Q4 		$23K Buy
+980
New +$23K ﹤0.01% 1303
2019
Q2 		– Sell
-2,421
Closed -$128K – 1447
2019
Q1 		$128K Sell
2,421
-2,239
-48% -$65.2K 0.01% 1090
2018
Q4 		$71K Buy
4,660
+3,737
+405% +$73.9K ﹤0.01% 1212
2018
Q3 		$24K Buy
+923
New +$30.1K ﹤0.01% 1388
2018
Q2 		– Sell
-486
Closed -$39K – 1970
2018
Q1 		$39K Buy
486
+234
+93% +$21.8K ﹤0.01% 1749
2017
Q4 		$12K Sell
252
-1
-0.4% -$73 ﹤0.01% 2259
2017
Q3 		$24K Buy
+253
New +$20.1K ﹤0.01% 2317

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Virtu Financial's ATOS Position: Q3 2025 in Review

Virtu Financial sold out of Atossa Therapeutics (ATOS) in Q3 2025, closing a stake of 2,451 shares — an estimated $31K sold.

Virtu Financial first reported a position in ATOS in Q3 2017 and held it in 18 quarters. The position peaked at $574K in Q1 2021. 66 funds tracked by Wall St. Rank hold ATOS as of Q3 2025.

  • Virtu Financial reported no remaining Atossa Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Virtu Financial sold 2,451 Atossa Therapeutics shares in Q3 2025, an estimated $31K.
  • Virtu Financial first reported a position in Atossa Therapeutics in Q3 2017 and held it in 18 quarters.
  • Virtu Financial's Atossa Therapeutics position peaked at $574K in Q1 2021.
  • 66 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2025.

Based on Virtu Financial's 13F filing for Q3 2025, filed 14 Nov 2025.